Journal of Cardiovascular Pharmacology · Nov 19, 2026
Modulating Platelet Reactivity with GLP-1RAs in Diabetes: Mechanistic Insights, Potential Benefits, and Clinical Limitations in Atherothrombotic Prevention
By Nusca A, Di Bitonto MP, Santella C et al.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have redefined cardiovascular medicine, reducing major adverse cardiovascular events (MACE) through pleiotropic mechanisms that transcend glycemic and weight control. While their cardioprotective benefits are well-established, their direct impact on platelet activity—a key driver of atherothrombotic risk—remains a compelling frontier. This narrative review first addresses the heightened atherothrombotic risk characteristic of patients with diabetes and the clinical challenges posed by their suboptimal response to standard antiplatelet regimens. Subsequently, it explores experimental evidence on the antiplatelet properties of GLP-1RAs. Mechanistically, GLP-1RAs exert a dual inhibitory action: direct modulation involves the activation of platelet-surface GLP-1 receptors, triggering the PKA signaling cascade and VASP phosphorylation, which in turn suppresses calcium mobilization and aggregation. Indirectly, these agents restore vascular health by enhancing nitric oxide bioavailability, preserving endothelial glycocalyx integrity, and shifting perivascular adipose tissue toward an anti-inflammatory phenotype. Furthermore, GLP-1RAs mitigate the pro-thrombotic milieu by attenuating glycemic variability and systemic inflammatory cascades. However, these compelling experimental findings do not currently translate into clear clinical impact, and a clinical gap persists: while reductions in mortality and stroke risk are firmly established, the specific efficacy of GLP-1RAs in preventing acute coronary events is still evolving. In conclusion, GLP-1RAs emerge as multifaceted tools with significant cardiovascular protection, offering a synergistic approach to secondary prevention in high-risk cardiometabolic patients; however, how these favorable outcomes are mediated by antiplatelet properties warrants dedicated prospective investigations to translate experimental findings into clinical certainty.
doi.org/10.1097/fjc.0000000000001903PubMed 43055514Interventions